Lifespin has launched its Therapeutic Drug Monitoring software for anti-infectives, meaning laboratories will be able to use the algorithm to gain measurements of antibiotics in the blood of patients.
Lifespin’s product utilises nuclear magnetic resonance (NMR) to test for commonly used antibiotics, including Ceftazidim, Cefuroxim, and Ceftriaxon. Other anti-infectives the product monitors for are Flucloxacillin, Piperacillin, Fluconazol, and Flucytosin. The test will also detect Cefotiam and Flucytosin for research use only.
The rollout of the test is via the company’s ‘plug-and-play’ cloud system. Licensed laboratories equipped with suitable hardware will be able to utilise Lifespin’s algorithm.
Based in Regensburg, Germany, Lifespin is targeting personalised medicine. The company says that providing insights into antibiotic levels from human serum samples can help physicians tailor treatments more effectively in sepsis treatment and respiratory tract infections such as pneumonia.
Many treatments work with different efficacies across individuals. Antibiotic resistance is a rising factor in barriers to effective treatments. Around 1.27 million people die each year worldwide due to antimicrobial resistance, with the disease burden greatest in low-income and middle-income countries. It is estimated that AMR will cause ten million deaths by 2050 unless action is taken.
According to GlobalData’s pipeline data, six antibiotic/antivirus therapeutic drug monitoring products are currently in active development.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
Your download email will arrive shortly
We are confident about the
quality of our Company Profiles. However, we want you to make the most
decision for your business, so we offer a free sample that you can download by
submitting the below form
Lifespin operates using a cloud-based model based on its diagnostics software-as-a-service platform. The company is currently developing tests for the detection of neurological, cancer, and inflammatory diseases. Lifespin states its products offered to date are for research use only.
Lifespin CEO Dr Ali Tinazli said: “Responding to market demands for enhanced antibiotic stewardship, we’ve made this groundbreaking technology accessible globally through our cloud-based system. This empowers laboratories worldwide to deliver personalised treatment options.”
In October 2023, ProciseDx secured US Food and Drug Administration clearance for its therapeutic drug monitoring tests. ProciseDx can measure adalimumab (Humira and biosimilar Amgevita) and infliximab (Remicade and biosimilars Inflectra and Renflexis).